GovChime
Notice ID: 03dd4ad0ceec495aaa3d1563e0072a23Award NoticeAwardedArchived

6505--Radiopharmaceuticals RMR VAMC 5-year IDIQ

Awarded on January 29, 2026. Full description on SAM.gov.

Awarded tounder 36C25926D0018 (source: SAM.gov award notice)• $0

Overview

Posted
January 29, 2026
Notice type
Award Notice
NAICS
325412: Pharmaceutical Preparation Manufacturing
Agency
Department of Veterans Affairs

Notice details

Office
NETWORK CONTRACT OFFICE 19 (36C259)
Place of performance
Department of Veterans Affairs Rocky Mountain Regional VAMC, Aurora, CO, 80045
Last updated
Nov 3, 2026
First published
Last updated on SAM.gov
Award date
Jan 29, 2026
Award amount (SAM.gov award notice)
$0

Identifiers

Solicitation number
36C25926Q0144
Notice ID
03dd4ad0ceec495aaa3d1563e0072a23
Award number (PIID)
36C25926D0018

Description

The purpose of this amendment is to answer questions that were received (see below) Q. Will the Government only consider a sole award, or will they consider a multi-award? A. This award will only be a sole award. Q. Would you be willing to separate the High Energy products from the Low Energy products on the products list, specifically, CLINs 0001 and 0002 on Base year and Option Years 1-4? A. No, we do not wish to separate the products

Full description on SAM.gov

Award Overview

Award Number

36C25926D0018

Award Amount (SAM.gov award notice)

$0

Award Date

Jan 29, 2026

Awardee

Awardee UEI

CWN9UGL3NCL9

Awardee CAGE Code

3S229

Awardee Address

DUBLIN, OH 43017, OH

Line Item Number

240

Original Solicitation

Notice ID: 03dd4ad0ceec495aaa3d1563e0072a23

Posted Date: Jan 29, 2026

Original Response Deadline: Not specified

Task Orders Under This IDV

Top 10 by total obligated

2
  • 36C25926N0227
    CARDINAL HEALTH 414, LLC
    Department of Veterans AffairsNAICS 325412
    $511.5KSigned Jan 30, 2026
  • 36C25926N0227
    CARDINAL HEALTH 414, LLC
    Department of Veterans AffairsNAICS 325412
    $511.5KSigned Feb 26, 2026

More From This Vendor

Top 5 most recent

5
  • 36C26125N0432
    CARDINAL HEALTH 414, LLC
    Department of Veterans AffairsNAICS 325412
    $387.3KSigned Nov 5, 2026
  • 36C24723P0302
    CARDINAL HEALTH 414, LLC
    Department of Veterans AffairsNAICS 325412
    $1.7MSigned Nov 4, 2026
  • 36C24726P0429
    CARDINAL HEALTH 414, LLC
    Department of Veterans AffairsNAICS 325412
    $68.9KSigned Nov 4, 2026
  • 36C26025N0381
    CARDINAL HEALTH 414, LLC
    Department of Veterans AffairsNAICS 325412
    $89.5KSigned Nov 4, 2026
  • 36C24724C0067
    CARDINAL HEALTH 414, LLC
    Department of Veterans AffairsNAICS 325412
    $604.1KSigned Nov 3, 2026

Contacts

Contracting Officer

Primary Contact

Chris Hollingsworth
Contract Specialist

Documents

Files (7)

  • 36C25926Q0144 0001.docx

    15 KBAdded in Combined Synopsis/Solicitation version 6Posted
    Download
  • Attachment 3 - Authorized Caller List.docx

    15 KBAdded in Combined Synopsis/Solicitation version 1Posted
    Download
  • Attachment 2 - FAR 52.225-2 Buy American Certificate.docx

    14 KBAdded in Combined Synopsis/Solicitation version 1Posted
    Download
  • Attachment 1 - Radiopharmaceutical Items.xlsx

    23 KBAdded in Combined Synopsis/Solicitation version 1Posted
    Download
  • SOW Radiopharmaceuticals.docx

    71 KBAdded in Combined Synopsis/Solicitation version 1Posted
    Download
  • 36C25926D0018_1.docx

    13 KBAdded in Award Notice version 4Posted
    Download
  • 36C25926Q0144.docx

    39 KBAdded in Combined Synopsis/Solicitation version 1Posted
    Download

Lifecycle

  1. 5
    Version 5Combined Synopsis/SolicitationArchived

    6505--Radiopharmaceuticals RMR VAMC 5-year IDIQ

    Notice 492137661dd44850b73953b3a8ec9b75 on SAM.gov

  2. 4
    Version 4Award NoticeArchivedCurrent

    Type changed from Combined Synopsis/Solicitation to Award Notice

    6505--Radiopharmaceuticals RMR VAMC 5-year IDIQ

    Notice 03dd4ad0ceec495aaa3d1563e0072a23 on SAM.gov

Other notices for this solicitation

  1. Combined SynopsisRelated noticeJan 8, 2026

    6505--Radiopharmaceuticals RMR VAMC 5-year IDIQ

    Notice 51f8c5f21e3041c39ef167dda4ef398a on SAM.gov

Similar Opportunities

Title
Match
Phase
Deadline
Sources Sought Notice - General Radioisotopes (Diagnostic & Therapeutic) Disclaimer: This Request for Information (RFI) is issued solely for market research information and planning purposes and does not constitute a solicitation. All information received in response to this RFI that is marked as proprietary will be handled accordingly. Responses to this notice are NOT offers and cannot be accepted by the Government to form a binding contract. Responders are solely responsible for all expenses associated with responding to this RFI. Information Requested from Industry: In response to the Sources Sought, interested Contractors shall submit the following information and any Capabilities/Qualifications Statement to include but not limited to an overview of proposed solution(s) and a description of the product your company possesses in accordance with the draft Statement of Work (SOW) / general requirement and deliverables list. Responses to market research questions shall be submitted. If this information is not provided, then it will be assumed the entire requirement cannot be met. Confirmation that interested party can meet the required timelines listed in draft SOW. Description of Requirement: The Department of Veterans Affairs, Veterans Health Administration (VHA), Network Contracting Office 19 (NCO 19) is conducting a market survey and is seeking potential sources for unit dose radiopharmaceuticals, radioactive sources, and supplies for diagnostic imaging exams and quality assurance procedures (brand name or equal) for the Salt Lake City VA Medical Center. This Sources Sought Notice is issued for information and planning purposes only. This is not a solicitation or a request for proposal and shall not be construed as an obligation or commitment by the Government. An award will not be made on any offers submitted in response to this notice, and it shall not be implied the Government is committed to providing any solicitation or award following this notice. The Government will not pay for any information received in response to this request, nor will the Government compensate a respondent for any costs incurred in developing the information provided. Please note that due to the degradation properties of the requested radioisotopes any potential awardee must comply with the delivery requirements contained in the attached statement of work and provide proof that the calibrated date and time constraints can be met. Due to radiological properties and hazardous nature of requested products, any potential awardee must hold all applicable licensing and management systems as outlined in the draft SOW. If you can provide, please answer the following questions: Vendor Name: Vendor POC: Vendor SAM ID #: Vendor business size status (SDVOSB, 8(a), small/large business): Estimated delivery/lead time: Manufacturer of the item(s): a) Name: b) Place of manufacture end product: c) Size status: Provide a list of Authorized distributors (if applicable): GSA/FSS Schedule contract # (if applicable): Y/N _____ Does not exceed 1,300 employees; (NAICS 325412 - must be verifiable thru the System for Award Management). If yes, how many employees? _____ Y/N _____ Is primarily engaged in the retail or wholesale trade and normally sells the type of item being supplied; Y/N _____ Takes ownership or possession of the item(s) with its personnel, equipment or facilities in a manner consistent with industry practice (identify how this occurs); **drop shipping is an acceptable way to take possession** and Y/N _____ Will supply the end item of a small business manufacturer, processor or producer made in the United States, or obtains a waiver of such requirement pursuant to paragraph (b)(5) CFR 121.406. NOTE: If you company is a distributor, of requested products, from a vendor other than yourself please provide a copy of the Authorized Distributor letter or Letter of Authorization (LOA) from that manufacturer. Response Instructions: Do not provide more than 8 pages, including cover letter page. Submit your response via email to mark.holland@va.gov Submit your response NLT 10:00 (MST) on Thursday, November 12, 2026; Mark your response as Proprietary Information if the information is considered business sensitive. VA has identified the appropriate North American Industry Classification System (NAICS) Code as 325412 (Pharmaceutical Preparation Manufacturing) with a Small Business size of 1,300 Employees. (End of Sources Sought)
-Market Research11/12/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Furoscix ReadyFlow – Diuretics – NA b. Gwyn Lo – Contraceptive Agents – Miscellaneous c. Jideytro – Lung Cancer – NA d. Omlyclo – Atopy – NA e. RizaFilm – Migraine Agents – NA f. Zenbexus – Multiple Myeloma – NA The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9403. Pre-Quotation Teleconference is on September 9, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
-Solicitation09/24/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 newly approved drugs will be reviewed: a. Awiqli Flextouch - Insulin - Basal b. Cavhanza - Leukemia and Lymphoma Agents - BCR-ABL Tyrosine Kinase Inhibitors c. Lipfendra - Antilipidemics-1 - PCSK-9 d. Trutakna - Nephrology Agents Miscellaneous - NA The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9402. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POC in Part 2.3.1., no later than the date stated in Part 2.3.2.
-Solicitation08/27/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following November 2026 drug classes/subclasses will be reviewed: a. Atopy - Topical Agents Anzupgo Eucrisa Opzelura Vtama Zoryve b. Lung Cancer - METEX14 Tabrecta Tepmetko The RFQ, including UF BPA and UF ADP appendices, are attached herein. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9401. Pre-quotation teleconference is on August 12, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference.
-Solicitation10/01/2026
The Department of War (DoW) is required by law (10 U.S.C. § 1074g) to establish an effective, efficient, integrated pharmacy benefits program for the Military Health System (MHS) which includes the purchase pharmaceutical agents. The law and implementing regulation (32 CFR Section 199.21) describe the process by which the DoW Pharmacy and Therapeutics (P&T) Committee will consider the relative clinical effectiveness and relative cost effectiveness of pharmaceutical agents in a therapeutic class in recommending the selection of agents for the DoW Uniform Formulary (UF) and, for cost sharing purposes, the classification of a pharmaceutical agent as generic, formulary, Basic Core Formulary (BCF), Extended Core Formulary (ECF), or non-formulary (NF). Prior to the scheduled P&T Committee meeting, a Request for Quotation (RFQ) for pharmaceutical agents within Drug Classes identified for placement on the UF has been issued to obtain quotes from industry. The Defense Health Agency may award Uniform Formulary Blanket Purchase Agreements (UF BPA) and the Uniform Formulary Additional Discount Program Agreements (UF ADP) based on the UF decision. This process is described in the attached RFQ. P&T COMMITTEE MEETING: The following August 2026 newly approved drugs will be reviewed: a. Atoncy – ADHD Agents – Subclass: Non-stimulants b. Baxfendy – Diuretics – Subclass: Mineralocorticoid Receptor Antagonists c. Duloxetine - Antidepressants And Non-opioid Pain Syndrome Agents – Subclass: SNRI d. Filkri – White Blood Cell Stimulants – Subclass: Filgrastims (Only ADP eligible due to non-TAA compliance) e. Hepcludex – Hepatitis D Agent – Subclass: NA f. Lynavoy – Gastrointestinal-2 Agents – Subclass: NA g. Veppanu - Breast Cancer Agents – Subclass: Estrogen Receptor Antagonist h. Xocova – Antivirals – Subclass: FDA Approved COVID Therapeutics i. Xtoro - Antibiotics – Subclass: Quinolones The RFQ, including UF BPA and UF ADP appendices are attached here in. The instructions, important deadlines, and points of contact are in document, RFQ HT9402-26-Q-9304. Pre-quotation teleconference is on July 15, 2026. Details are stated in Part 2.4. Pre-Quotation Teleconference. Responses to the clinical questions in Part 3.4 shall be submitted via e-mail to the RFQ POCs in Part 2.3.1., no later than the date stated in Part 2.3.2.
-Solicitation07/27/2026

Additional Details

Solicitation Number

36C25926Q0144

Archive Date

Feb 28, 2026

Office Address

Greenwood Village, CO, 80111